The board / CagriSema vs Semaglutide 2.4 mg
Injectable division

CagriSema

AClass-leading
Novo Nordisk · certified
vs
Injectable division

Semaglutide 2.4 mg (Wegovy)

CompetitiveB
Novo Nordisk · approved
17% · leads
Efficacy
12%
Mild (+2.3)
Tolerability
Mild (+3.9)
Subcutaneous injection
Route
Subcutaneous injection
None
Food / water rule
None
Refrigerated
Storage
Refrigerated (room temperature up to 28 days)
The call: CagriSema leads on efficacy: class leading to Semaglutide 2.4 mg's competitive (17% vs 12%). Tolerability is a wash: both Mild.
Standalone, this page carries its own key: Efficacy = % body weight lost vs placebo, on the conservative estimand that counts everyone. Tolerability = AE-discontinuation over placebo (Mild 1 to 5 · Notable 5 to 10 · Heavy over 10 points). Winners are called only across a tier or band boundary; within one, the drugs are effectively tied. The side marked leads or gentler wins that axis.

CagriSema verdict · Semaglutide 2.4 mg verdict · How this is scored